Minnesota is currently home to 2108 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
NCT05180708
Recruiting
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: Minnesota Clinical Study Center, Fridley, Minnesota
Conditions: Pachyonychia Congenita
Register for Updates
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
NCT05050149
Recruiting
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Gender:
All
Ages:
13 years and above
Trial Updated:
08/26/2022
Locations: Minnesota Clinical Study Center, Fridley, Minnesota
Conditions: Microcystic Lymphatic Malformation
Register for Updates
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
NCT04893486
Recruiting
A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 mon... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: Clinical Coordinating Center (Minnesota), New Brighton, Minnesota
Conditions: BCCs in Gorlin Syndrome Patients
Register for Updates
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Chemical and/or Thermal Injuries
NCT04081103
Recruiting
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epi... Read More
Gender:
All
Ages:
All
Trial Updated:
08/25/2022
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Corneal Persistent Epithelial Defect
Register for Updates
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
NCT05305911
Recruiting
The purpose of the research is to determine whether a medication called dapagliflozin will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking the medication dapagliflozin (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/04/2022
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Heart Attack, Enlarged Heart
Register for Updates
Endorotor Resection In Refractory Barrett's Dysplasia Patients
NCT03364114
Recruiting
The aim of the clinical trial is to evaluate the EndoRotor®'s ability to completely remove areas of Barrett's esophagus considered refractory after 3 failed ablation treatments (Radiofrequency Ablation (RFA) and/or Cryotherapy) or in patients with at least 1 failed ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duratio... Read More
Gender:
All
Ages:
Between 30 years and 89 years
Trial Updated:
08/01/2022
Locations: The Mayo Clinic, Rochester, Minnesota
Conditions: Barrett's Esophagus With Dysplasia
Register for Updates
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
NCT01694940
Recruiting
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
Gender:
All
Ages:
All
Trial Updated:
07/28/2022
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Register for Updates
USCRI Ready4Life Program
NCT05476185
Recruiting
The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines,... Read More
Gender:
All
Ages:
Between 14 years and 18 years
Trial Updated:
07/25/2022
Locations: Internationa Institute of Minnesota, Saint Paul, Minnesota
Conditions: Communication, Problem Solving, Social Relationships, Economic Stability
Register for Updates
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
NCT05187351
Recruiting
The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention (PCI) of the corresponding native coronary artery.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2022
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Target Vessel Failure in Saphenous Vein Grafts, Percutaneous Coronary Intervention
Register for Updates
Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
NCT04077762
Recruiting
This is a phase IV, prospective, open label, randomized-controlled study that will compare radial access with state-of-the-art femoral access in patients without ST-segment elevation acute myocardial infarction undergoing cardiac catheterization. Subjects will be randomized 1:1 into 2 treatment groups: radial access and state-of-the-art femoral access. Randomization will be performed in blocks of 50 per site. Similarly, a second sub-randomization will be performed in the femoral access group int... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/27/2022
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Patient Satisfaction, Vascular Access Complication
Register for Updates
Artisan Aphakia Lens for the Correction of Aphakia in Children
NCT01547442
Recruiting
The purpose of this study is to determine the safety and effectiveness of the Artisan Aphakia Lens in the treatment of aphakia in children.
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
06/24/2022
Locations: University of Minnesota, MN Lions Children's Eye Clinic, Minneapolis, Minnesota
Conditions: Aphakia
Register for Updates
Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients
NCT04083690
Recruiting
Cardiac resynchronization therapy (CRT), or atrial-synchronized biventricular (BiV) pacing, is an FDA-approved device therapy option for heart failure (HF) patients with reduced left ventricular ejection fraction and electrical dyssynchrony. A traditional CRT device has pacing leads implanted within the right atrium (RA), the right ventricle (RV), and within a coronary vein overlying the lateral or posterior left ventricle (LV). Within the past decade, various multi-center randomized controlled... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/08/2022
Locations: Minneapolis Heart Institute (Abbott Northwestern Hospital), Minneapolis, Minnesota
Conditions: Heart Failure, Systolic
Register for Updates